{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:33:34Z","timestamp":1788838414661,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bmc.2026.118735","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:24:37Z","timestamp":1782343477000},"page":"118735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Recent advances in the development of small-molecule drugs based on covalent reversible inhibitors"],"prefix":"10.1016","volume":"140","author":[{"given":"Zi","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiubo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bmc.2026.118735_bb0005","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00044-023-03065-3","article-title":"An update on the discovery and development of reversible covalent inhibitors","volume":"32","author":"Faridoon","year":"2023","journal-title":"Med Chem Res"},{"issue":"12","key":"10.1016\/j.bmc.2026.118735_bb0010","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00726-023-03286-1","article-title":"Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories","volume":"55","author":"Feral","year":"2023","journal-title":"Amino Acids"},{"issue":"6","key":"10.1016\/j.bmc.2026.118735_bb0015","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1021\/acsmedchemlett.4c00113","article-title":"Identification and evaluation of reversible covalent binders to Cys55 of Bfl-1 from a DNA-encoded chemical library screen","volume":"15","author":"SCC","year":"2024","journal-title":"ACS Med Chem Lett"},{"issue":"14","key":"10.1016\/j.bmc.2026.118735_bb0020","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1021\/ja401221b","article-title":"Electrophilic fragment-based Design of Reversible Covalent Kinase Inhibitors","volume":"135","author":"Miller","year":"2013","journal-title":"J Am Chem Soc"},{"issue":"5","key":"10.1016\/j.bmc.2026.118735_bb0025","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nchembio.925","article-title":"Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles","volume":"8","author":"Serafimova","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2026.118735_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105673","article-title":"Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors","volume":"121","author":"Nie","year":"2022","journal-title":"Bioorg Chem"},{"issue":"31","key":"10.1016\/j.bmc.2026.118735_bb0035","doi-asserted-by":"crossref","first-page":"17131","DOI":"10.1002\/anie.202105383","article-title":"Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL inhibitors**","volume":"60","author":"Quach","year":"2021","journal-title":"Angew Chem Int Ed"},{"issue":"85","key":"10.1016\/j.bmc.2026.118735_bb0040","doi-asserted-by":"crossref","first-page":"12437","DOI":"10.1039\/D4CC04612A","article-title":"New electrophiles targeting thiols in a reversible covalent manner","volume":"60","author":"Ma","year":"2024","journal-title":"Chem Commun"},{"issue":"33","key":"10.1016\/j.bmc.2026.118735_bb0045","doi-asserted-by":"crossref","first-page":"11385","DOI":"10.1002\/anie.201905829","article-title":"The proteome-wide potential for reversible covalency at cysteine","volume":"58","author":"Senkane","year":"2019","journal-title":"Angew Chem Int Ed"},{"issue":"5","key":"10.1016\/j.bmc.2026.118735_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.110203","article-title":"Isotope-labeled click-free probes to identify protein targets of lysine-targeting covalent reversible molecules","volume":"36","author":"Ma","year":"2025","journal-title":"Chin Chem Lett"},{"issue":"25","key":"10.1016\/j.bmc.2026.118735_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202505581","article-title":"Proteome-wide data guides the discovery of lysine-targeting covalent inhibitors using DNA-encoded chemical libraries","volume":"64","author":"Wu","year":"2025","journal-title":"Angew Chem Int Ed"},{"issue":"7","key":"10.1016\/j.bmc.2026.118735_bb0060","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1021\/acs.jmedchem.1c01170","article-title":"Discovery of reversible covalent Bruton\u2019s tyrosine kinase inhibitors PRN473 and PRN1008 (Rilzabrutinib)","volume":"65","author":"Owens","year":"2022","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.bmc.2026.118735_bb0065","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1021\/acs.jmedchem.8b00571","article-title":"Development, optimization, and structure\u2013activity relationships of covalent-reversible JAK3 inhibitors based on a tricyclic imidazo[5,4- d ]pyrrolo[2,3- b ]pyridine scaffold","volume":"61","author":"Forster","year":"2018","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.bmc.2026.118735_bb0070","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1016\/j.bmc.2015.04.038","article-title":"Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR","volume":"23","author":"Basu","year":"2015","journal-title":"Bioorg Med Chem"},{"issue":"13","key":"10.1016\/j.bmc.2026.118735_bb0075","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1021\/acs.jmedchem.9b00387","article-title":"Application of dually activated Michael acceptor to the rational Design of Reversible Covalent Inhibitor for enterovirus 71 3C protease","volume":"62","author":"Ma","year":"2019","journal-title":"J Med Chem"},{"issue":"6575","key":"10.1016\/j.bmc.2026.118735_bb0080","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.bmc.2026.118735_bb0085","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1021\/jm050261p","article-title":"Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Augeri","year":"2005","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.bmc.2026.118735_bb0090","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1021\/acs.jmedchem.6b01127","article-title":"Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane Amidoacetonitrile based clinical candidate (AZD7986)","volume":"59","author":"Doyle","year":"2016","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2026.118735_bb0095","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bmcl.2007.12.047","article-title":"The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K","volume":"18","author":"Gauthier","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"24","key":"10.1016\/j.bmc.2026.118735_bb0100","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1021\/jm0504961","article-title":"Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity","volume":"48","author":"Falgueyret","year":"2005","journal-title":"J Med Chem"},{"issue":"16","key":"10.1016\/j.bmc.2026.118735_bb0105","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/cbic.201402321","article-title":"Reversible covalent inhibition of eEF-2K by carbonitriles","volume":"15","author":"Devkota","year":"2014","journal-title":"ChemBioChem"},{"issue":"21","key":"10.1016\/j.bmc.2026.118735_bb0110","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1021\/acs.jmedchem.0c01019","article-title":"Discovery of Roblitinib (FGF401) as a reversible-covalent inhibitor of the kinase activity of fibroblast growth factor receptor 4","volume":"63","author":"Fairhurst","year":"2020","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118735_bb0115","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1021\/acs.jmedchem.3c01810","article-title":"Discovery of 6-Formylpyridyl urea derivatives as potent reversible-covalent fibroblast growth factor receptor 4 inhibitors with improved anti-hepatocellular carcinoma activity","volume":"67","author":"Yang","year":"2024","journal-title":"J Med Chem"},{"issue":"16","key":"10.1016\/j.bmc.2026.118735_bb0120","doi-asserted-by":"crossref","first-page":"12322","DOI":"10.1021\/acs.jmedchem.1c01002","article-title":"Fluorovinylsulfones and -sulfonates as potent covalent reversible inhibitors of the trypanosomal cysteine protease rhodesain: structure\u2013activity relationship, inhibition mechanism, metabolism, and in vivo studies","volume":"64","author":"Jung","year":"2021","journal-title":"J Med Chem"},{"issue":"13","key":"10.1016\/j.bmc.2026.118735_bb0125","doi-asserted-by":"crossref","first-page":"9130","DOI":"10.1021\/acs.jmedchem.3c00737","article-title":"Expanding the chemistry of Dihaloacetamides as Tunable electrophiles for reversible covalent targeting of cysteines","volume":"66","author":"Yamane","year":"2023","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2026.118735_bb0130","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1021\/acs.jmedchem.3c02076","article-title":"Reinvent aliphatic arsenicals as reversible covalent warheads toward targeted kinase inhibition and non-acute promyelocytic leukemia cancer treatment","volume":"67","author":"Zhao","year":"2024","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118735_bb0135","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1038\/s41467-024-52573-2","article-title":"Reversible covalent c-Jun N-terminal kinase inhibitors targeting a specific cysteine by precision-guided Michael-acceptor warheads","volume":"15","author":"B\u00e1lint","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.bmc.2026.118735_bb0140","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.chembiol.2018.06.001","article-title":"The Meisenheimer complex as a paradigm in drug discovery: reversible covalent inhibition through C67 of the ATP binding site of PLK1","volume":"25","author":"Pearson","year":"2018","journal-title":"Cell Chem Biol"},{"issue":"11","key":"10.1016\/j.bmc.2026.118735_bb0145","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nchembio.2174","article-title":"Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain","volume":"12","author":"Ak\u00e7ay","year":"2016","journal-title":"Nat Chem Biol"},{"issue":"3","key":"10.1016\/j.bmc.2026.118735_bb0150","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/jacs.1c12702","article-title":"Lysine-targeting reversible covalent inhibitors with long residence time","volume":"144","author":"Reja","year":"2022","journal-title":"J Am Chem Soc"},{"issue":"52","key":"10.1016\/j.bmc.2026.118735_bb0155","doi-asserted-by":"crossref","first-page":"17178","DOI":"10.1002\/anie.201811650","article-title":"Affinity enhancement of protein ligands by reversible covalent modification of Neighboring lysine residues","volume":"57","author":"Dal\u00a0Corso","year":"2018","journal-title":"Angew Chem Int Ed"},{"issue":"11","key":"10.1016\/j.bmc.2026.118735_bb0160","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1021\/acsptsci.3c00156","article-title":"Targeted reversible covalent modification of a noncatalytic lysine of the Krev interaction trapped 1 protein enables site-directed screening for protein\u2013protein interaction inhibitors","volume":"6","author":"Francisco","year":"2023","journal-title":"ACS Pharmacol Transl Sci."},{"issue":"21","key":"10.1016\/j.bmc.2026.118735_bb0165","doi-asserted-by":"crossref","first-page":"19546","DOI":"10.1021\/acs.jmedchem.4c01876","article-title":"Achieving high affinity for a bacterial lectin with reversible covalent ligands","volume":"67","author":"Antonini","year":"2024","journal-title":"J Med Chem"},{"issue":"8044","key":"10.1016\/j.bmc.2026.118735_bb0170","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41586-024-08176-4","article-title":"Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation","volume":"637","author":"Craven","year":"2025","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bmc.2026.118735_bb0175","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy","volume":"5","author":"Teicher","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bmc.2026.118735_bb0180","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bmc.2026.118735_bb0185","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.bmc.2026.118735_bb0190","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs class A serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2026.118735_bb0195","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease","volume":"50","author":"Perni","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.bmc.2026.118735_bb0200","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.50.3.1013-1020.2006","article-title":"SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells","volume":"50","author":"Malcolm","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.bmc.2026.118735_bb0205","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/jpet.120.000219","article-title":"Targeting Enteropeptidase with reversible covalent inhibitors to achieve metabolic benefits","volume":"375","author":"Sun","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.bmc.2026.118735_bb0210","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1021\/acsptsci.3c00281","article-title":"Structure-based identification of Kelch-like ECH-associated protein 1 as a pharmacological target of electrophile-containing catechol- O -methyltransferase inhibitors","volume":"7","author":"Wang","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"12","key":"10.1016\/j.bmc.2026.118735_bb0215","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/nchembio.1666","article-title":"Covalent docking of large libraries for the discovery of chemical probes","volume":"10","author":"London","year":"2014","journal-title":"Nat Chem Biol"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:52:32Z","timestamp":1783003952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"alternative-id":["S0968089626001914"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118735","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the development of small-molecule drugs based on covalent reversible inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118735"}}